Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer
![]() |
Hong, Jun-Shik
(Department of Internal Medicine, Gachon University Gil Hospital, Gachon University of Medicine and Science Graduate School of Medicine)
Kyung, Sun-Young (Department of Internal Medicine, Gachon University Gil Hospital, Gachon University of Medicine and Science Graduate School of Medicine) Lee, Sang-Pyo (Department of Internal Medicine, Gachon University Gil Hospital, Gachon University of Medicine and Science Graduate School of Medicine) Park, Jeong-Woong (Department of Internal Medicine, Gachon University Gil Hospital, Gachon University of Medicine and Science Graduate School of Medicine) Jung, Sung-Hwan (Department of Internal Medicine, Gachon University Gil Hospital, Gachon University of Medicine and Science Graduate School of Medicine) Lee, Jae-Ik (Department of Thoracic Surgery, Gachon University Gil Hospital, Gachon University of Medicine and Science Graduate School of Medicine) Park, Se-Hoon (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) Sym, Sun-Jin (Department of Internal Medicine, Gachon University Gil Hospital, Gachon University of Medicine and Science Graduate School of Medicine) Park, Jinny (Department of Internal Medicine, Gachon University Gil Hospital, Gachon University of Medicine and Science Graduate School of Medicine) Cho, Eun-Kyung (Department of Internal Medicine, Gachon University Gil Hospital, Gachon University of Medicine and Science Graduate School of Medicine) Shin, Dong-Bok (Department of Internal Medicine, Gachon University Gil Hospital, Gachon University of Medicine and Science Graduate School of Medicine) Lee, Jae-Hoon (Department of Internal Medicine, Gachon University Gil Hospital, Gachon University of Medicine and Science Graduate School of Medicine) |
1 | Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall- cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537. DOI ScienceOn |
2 | Korean Health Insurance Review and Assessment Service [Internet]. Korean Health Insurance Review and Assessment Service Announcement No. 2009-1. Seoul: Korean Health Insurance Review and Assessment Service, c2009 [cited 2009 Jan 01]. Available from: http://www.hira.or.kr/common/ dummy.jsp?pgmid=HIRAA030103000000. |
3 | Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551. DOI ScienceOn |
4 | National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) [Internet]. Bethesda (MD): National Cancer Institute - Cancer Therapy Evaluation Program, 2006 [cited at 2010 Jul 2]. Available from: http://ctep.cancer.gov/ protocolDevelopment/electronic_applications/ctc.htm#ctc_30. |
5 | Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909. DOI ScienceOn |
6 | Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237-2246. DOI ScienceOn |
7 | Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. DOI ScienceOn |
8 | Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158. DOI ScienceOn |
9 | Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-1818. DOI ScienceOn |
10 | Boysen M, Longson C, Stevens A. Erlotinib for the treatment of non-small-cell lung cancer. Lancet Oncol 2009;10:15-16. DOI ScienceOn |
11 | Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998;16:2459-2465. |
12 | Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall- cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103. |
13 | Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-smallcell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597. DOI ScienceOn |
14 | Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98. DOI ScienceOn |
15 | Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132. DOI ScienceOn |
16 | Yoo KY. Cancer control activities in the Republic of Korea. Jpn J Clin Oncol 2008;38:327-333. DOI ScienceOn |
17 | Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30. DOI ScienceOn |
18 | Stinchcombe TE, Socinski MA. Considerations for second-line therapy of non-small cell lung cancer. Oncologist 2008;13 Suppl 1:28-36. |
19 | Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000;18:122-130. |
![]() |